FBLG: Diabetic Foot Ulcer Trial of CYWC628 to Initiate in 1Q26
On October 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the third quarter of 2025 and provided a business update. The...
397 Views
FBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies
On September 10, 2025, FibroBiologics, Inc. (FBLG) announced significant advancements in the company's Bone Marrow Organoid platform that could...
270 Views
FBLG: Closes Third Tranche of 5M
On July 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the second quarter of 2025 and provided a business update. The...
165 Views
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis
On May 14, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the first quarter of 2025 and provided a business update. The company...
192 Views
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25
On March 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for 2024 and provided a business update. In preparation for the...
215 Views